



VIA UPS

March 29, 2017

Alexandra Blasi, Executive Secretary
Kansas State Board of Pharmacy
800 SW Jackson, Suite 1414
Topeka, KS 66612

Dear Ms. Blasi,

The purpose of this letter is to notify the Kansas State Board of Pharmacy (BOP) that the U.S. Food and Drug Administration (FDA) does not intend to take further action with regard to an inspection of a pharmacy licensed by the Kansas BOP, Perry Drugs, Inc., located at 12200 W 106th St., Ste 140, Overland Park, KS 66215-2305 (License #: 2-13040).

FDA inspected the firm from November 10, 2015, to November 13, 2015. The Kansas BOP was informed of the inspection but did not accompany FDA investigators during the inspection. No Form FDA 483 was issued to the firm.

During the inspection, the FDA investigators reviewed a small sample of records for products compounded by Perry Drugs, Inc. and determined, based on this sample, that this firm appears to obtain valid prescriptions for individually-identified patients for the drug products that it compounds and distributes.

FDA does not intend to take further action with regard to the findings of this inspection. Please notify us if you become aware of any adverse events or product quality concerns associated with drugs made at this facility, or if you observe any practices at this facility that concern you or that could be violations of Federal law.

We look forward to continuing to work with you on the oversight of compounding pharmacies. If you have additional questions, please contact Amy Devine, Compliance Officer, at (913) 495-5147, or by email at Amy.Devine@fda.hhs.gov.

Sincerely,

Cheryl A. Bigham -S

Digitally signed by Cheryl A. Bigham -S
DN: cn=Cheryl A. Bigham -S, o=U.S. Government, ou=FDA,
ou=People, ou=202, ou=1000001001, ou=100012001,
ou=Cheryl A. Bigham -S
Date: 2017.03.29 14:34:00 -0500

Cheryl A. Bigham
District Director
Kansas City District Office